Evaluation of Different Stabilizers and Inactivating Compounds for the Enhancement of Vero Cell Rabies Vaccine Stability and Immunogenicity: Study

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2019 Apr 23

PMID 31008105

Citations 5

Authors

Ebtesam Olayan

Manal El-Khadragy

Aly Fahmy Mohamed

Amany Khalil Mohamed

Rania Ibrahim Shebl

Hany M Yehia

Affiliations

Soon will be listed here.

Abstract

Inactivation of rabies virus is essential for rabies vaccine preparation where the inactivating compound that is currently recommended for rabies vaccine preparation is -propiolactone (-PL). This compound is considered better than phenol and formalin but it is expensive and potentially carcinogenic. Data revealed that Ascorbic acid (AA) with cupric ions could yield complete and irreversible inactivation of rabies virus without adversely affecting its antigenicity. Additionally, the results of testing the vaccine potency with the selected inactivating compounds were comparable (P<0.05), and ED was higher than the recommended World Health Organization (WHO) limits. The use of HemaGel (plasma substitute) for testing vaccine stabilization was compared with the currently used vaccine stabilizers (human albumin and lactose). HemaGel yielded better stability than the other tested stabilizers. Monitoring of cellular and humoral immune responses indicated that both the total IgG level against rabies vaccine and the IFN and IL5 levels obtained with the HemaGel-stabilized vaccines were higher than those obtained with human albumin- and lactose-stabilized vaccine candidates.

Citing Articles

Rabies Vaccine for Prophylaxis and Treatment of Rabies: A Narrative Review.

Kaye A, Perilloux D, Field E, Orvin C, Zaheri S, Upshaw W Cureus. 2024; 16(6):e62429.

PMID: 39011185 PMC: 11248466. DOI: 10.7759/cureus.62429.

Developments in Rabies Vaccines: The Path Traversed from Pasteur to the Modern Era of Immunization.

Natesan K, Isloor S, Vinayagamurthy B, Ramakrishnaiah S, Doddamane R, Fooks A Vaccines (Basel). 2023; 11(4).

PMID: 37112668 PMC: 10147034. DOI: 10.3390/vaccines11040756.

In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine.

Abd-Elghaffar A, Rashed M, Ali A, Amin M Vaccines (Basel). 2020; 8(4).

PMID: 33066050 PMC: 7712366. DOI: 10.3390/vaccines8040601.

What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist.

Palatnik-de-Sousa C Front Immunol. 2020; 11:2173.

PMID: 32983183 PMC: 7479216. DOI: 10.3389/fimmu.2020.02173.

Carcinogenesis of β-Propiolactone: A Computational Study.

Spaninger E, Bren U Chem Res Toxicol. 2020; 33(3):769-781.

PMID: 32056425 PMC: 7308071. DOI: 10.1021/acs.chemrestox.9b00389.

References

White L, Freeman C, Forrester B, Chappell W . In vitro effect of ascorbic acid on infectivity of herpesviruses and paramyxoviruses. J Clin Microbiol. 1986; 24(4):527-31. PMC: 268964. DOI: 10.1128/jcm.24.4.527-531.1986. View

Sonoda E, Matsumoto R, Hitoshi Y, Ishii T, Sugimoto M, Araki S . Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production. J Exp Med. 1989; 170(4):1415-20. PMC: 2189486. DOI: 10.1084/jem.170.4.1415. View

Swain S, McKenzie D, Dutton R, Tonkonogy S, English M . The role of IL4 and IL5: characterization of a distinct helper T cell subset that makes IL4 and IL5 (Th2) and requires priming before induction of lymphokine secretion. Immunol Rev. 1988; 102:77-105. DOI: 10.1111/j.1600-065x.1988.tb00742.x. View

Venkataswamy M, Madhusudana S, Sanyal S, Taj S, Belludi A, Mani R . Cellular immune response following pre-exposure and postexposure rabies vaccination by intradermal and intramuscular routes. Clin Exp Vaccine Res. 2015; 4(1):68-74. PMC: 4313111. DOI: 10.7774/cevr.2015.4.1.68. View

Sugiyama M, Ito N . Control of rabies: epidemiology of rabies in Asia and development of new-generation vaccines for rabies. Comp Immunol Microbiol Infect Dis. 2007; 30(5-6):273-86. DOI: 10.1016/j.cimid.2007.05.007. View

Rooijakkers E, Uittenbogaard J, Groen J, Osterhaus A . Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing. J Virol Methods. 1996; 58(1-2):111-9. DOI: 10.1016/0166-0934(95)01999-5. View

Bensink Z, Spradbrow P . Newcastle disease virus strain I2--a prospective thermostable vaccine for use in developing countries. Vet Microbiol. 1999; 68(1-2):131-9. DOI: 10.1016/s0378-1135(99)00069-3. View

Maloy K, Burkhart C, Freer G, Rulicke T, Pircher H, Kono D . Qualitative and quantitative requirements for CD4+ T cell-mediated antiviral protection. J Immunol. 1999; 162(5):2867-74. View

. Production in Vero cells of an inactivated rabies vaccine from strain FRV/K for animal and human use. Acta Virol. 1987; 31(4):321-8. View

10.

IMAM I, El-Karamany R . Preliminary studies on goat kidney cell culture as a possible substrate for veterinary RVF vaccine. J Egypt Public Health Assoc. 1978; 53(3-4):253-4. View

11.

Ramos T . Interleukin 5 is a differentiation factor for cytotoxic T lymphocytes. Immunol Lett. 1989; 21(4):277-83. DOI: 10.1016/0165-2478(89)90020-5. View

12.

Zhang J, Lindup W . Tiopronin protects against the nephrotoxicity of cisplatin in rat renal cortical slices in vitro. Toxicol Appl Pharmacol. 1996; 141(2):425-33. DOI: 10.1006/taap.1996.0308. View

13.

Forsell M, Li Y, Sundback M, Svehla K, Liljestrom P, Mascola J . Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus. J Virol. 2005; 79(17):10902-14. PMC: 1193613. DOI: 10.1128/JVI.79.17.10902-10914.2005. View

14.

Wit M, Horzinek M, Haagmans B, Schijns V . Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-12 or IFN-alpha/beta. J Gen Virol. 2004; 85(Pt 4):795-803. DOI: 10.1099/vir.0.19605-0. View

15.

Eichelberger M, Allan W, Zijlstra M, Jaenisch R, Doherty P . Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med. 1991; 174(4):875-80. PMC: 2118969. DOI: 10.1084/jem.174.4.875. View

16.

Blackburn N, Besselaar T . A study of the effect of chemical inactivants on the epitopes of Rift Valley fever virus glycoproteins using monoclonal antibodies. J Virol Methods. 1991; 33(3):367-74. DOI: 10.1016/0166-0934(91)90036-y. View

17.

Plotkin S . Vaccine production in human diploid cell strains. Am J Epidemiol. 1971; 94(4):303-6. DOI: 10.1093/oxfordjournals.aje.a121323. View

18.

Burke C, Hsu T, Volkin D . Formulation, stability, and delivery of live attenuated vaccines for human use. Crit Rev Ther Drug Carrier Syst. 1999; 16(1):1-83. View

19.

Howe R, Dhiman N, Ovsyannikova I, Poland G . Induction of CD4 T cell proliferation and in vitro Th1-like cytokine responses to measles virus. Clin Exp Immunol. 2005; 140(2):333-42. PMC: 1809354. DOI: 10.1111/j.1365-2249.2005.02766.x. View

20.

Cohen A, Boyer J, Weiner D . Modulating the immune response to genetic immunization. FASEB J. 1998; 12(15):1611-26. View